Mineralys CEO sells 10,700 shares under trading plan

Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported an open-market sale of 10,700 shares of common stock on July 13, 2026 at a weighted-average price of $27.2375 per share.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported an open-market sale of 10,700 shares of common stock on July 13, 2026 at a weighted-average price of $27.2375 per share. The transactions were effected under a Rule 10b5-1 trading plan adopted on January 28, 2025, and Congleton now holds 603,621 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 10,700 shares

Net Sell 1 txn

Insider Congleton Jon

Role Chief Executive Officer

Sold 10,700 shs ($291K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	10,700	$27.2375	$291K

Holdings After Transaction: Common Stock — 603,621 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Key Figures

Shares sold: 10,700 shares Weighted-average sale price: $27.2375 per share Post-transaction holdings: 603,621 shares +2 more

5 metrics

Shares sold 10,700 shares Common stock sold in open-market transaction on July 13, 2026

Weighted-average sale price $27.2375 per share Average price for reported 10,700-share sale

Post-transaction holdings 603,621 shares Common shares directly held by CEO after the sale

Trade price range $26.80–$27.58 per share Range of individual trade prices within the reported sale

10b5-1 plan adoption date January 28, 2025 Date CEO’s Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Mineralys Therapeutics (MLYS) report for CEO Jon Congleton?

Mineralys Therapeutics reported that CEO Jon Congleton executed an open-market sale of 10,700 common shares on July 13, 2026. The sale was made at a weighted-average price of $27.2375 per share under a pre-arranged Rule 10b5-1 plan.

At what price did the Mineralys Therapeutics (MLYS) CEO sell shares?

The CEO’s reported sale used a weighted-average price of $27.2375 per share. Footnote disclosure states the individual trades ranged from $26.80 to $27.58, with multiple transactions contributing to the reported average price.

How many Mineralys Therapeutics (MLYS) shares does the CEO hold after this Form 4 sale?

After the July 13, 2026 transaction, CEO Jon Congleton directly holds 603,621 shares of Mineralys Therapeutics common stock. This figure reflects his position following the open-market sale of 10,700 shares disclosed in the Form 4 filing.

Was the Mineralys Therapeutics (MLYS) CEO sale under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on January 28, 2025. Such plans pre-schedule trades, reducing the significance of the timing of these sales for interpreting insider sentiment.

What type of transaction did Mineralys Therapeutics (MLYS) disclose for its CEO?

The company disclosed an open-market sale of common stock by its CEO, coded as an “S” transaction. This represents a non-derivative sale of 10,700 shares, executed in multiple trades within a specified price range on July 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 08:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/13/2026		S(1)		10,700	D	$27.2375(2)	603,621	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 28, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.58. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)